Literature DB >> 1159815

Increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice.

F Campanile, D P Houchens, M Gaston, A Goldin, E Bonmassar.   

Abstract

Highly immunogenic sublines of L1210 and LSTRA lymphomas were obtained from athymic (nude) mice treated with 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)carboxamide (DIC) in vivo. Conventional mice, compatible with the parent tumor, rejected the DIC-treated sublines and were relatively resistant to a subsequent challenge with the parent lines. The DIC-treated sublines were not rejected by athymic mice, which indicated that the transplantation resistance to these tumors in conventional mice was thymus-cell dependent. In addition, there was marginal or no increase of tumor-cell immunogenicity when the parent lines were passaged in nude mice without DIC treatment. This indicated that the DIC-dependent immunogenic changes in DIC-treated leukemic conventional mice could not be ascribed merely to protection by naturally occurring antigenic clones that resulted from DIC-induced immunodepression.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159815     DOI: 10.1093/jnci/55.1.207

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  5 in total

1.  Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC).

Authors:  P Puccetti; A Giampietri; M C Fioretti
Journal:  Experientia       Date:  1978-06-15

Review 2.  Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.

Authors:  R S Kerbel; J W Dennis; A E Largarde; P Frost
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

Review 3.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 4.  Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

Authors:  Ornella Franzese; Francesco Torino; Maria Pia Fuggetta; Angelo Aquino; Mario Roselli; Enzo Bonmassar; Anna Giuliani; Stefania D'Atri
Journal:  Oncotarget       Date:  2017-06-20

5.  DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.

Authors:  O Marelli; P Franco; G Canti; L Ricci; N Prandoni; A Nicolin; H Festenstein
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.